drugset / Trial / NCT04952272
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
Phase 1
Recruiting
50 enrolled
Second Affiliated Hospital of Guangzhou Medical University
Guangdong Zhaotai InVivo Biomedicine Co. Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
To study the safety and clinical effects of intratumor injecting CpG-ODN and in situ release of tumor antigen by interventional ablation or drug-eluting beads to treat advanced solid tumors.
Timeline
- Start
- 2021-03-01
- Primary completion
- 2029-06-30
- Completion
- 2036-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-T cells secreting scFv against OX40 | Cell therapy | — | Other |
| Subject | GNKG168 | Oligonucleotide (other) | — | Other |